Your browser doesn't support javascript.
loading
Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy.
Zheng, Zhikai; Wang, Jiongliang; Wu, Tianqing; He, Minrui; Wang, Juncheng; Pan, Yangxun; Chen, Jinbin; Hu, Dandan; Xu, Li; Zhang, Yaojun; Chen, Minshan; Zhou, Zhongguo.
Afiliação
  • Zheng Z; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
  • Wang J; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
  • Wu T; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
  • He M; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
  • Wang J; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
  • Pan Y; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
  • Chen J; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
  • Hu D; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
  • Xu L; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
  • Zhang Y; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
  • Chen M; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
  • Zhou Z; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
J Hepatocell Carcinoma ; 10: 2117-2132, 2023.
Article em En | MEDLINE | ID: mdl-38053944
ABSTRACT

Purpose:

The efficacy of entecavir (ETV) versus tenofovir (TDF) on the prognosis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients who underwent FOLFOX-hepatic arterial infusion chemotherapy (HAIC) remains unclear. In this study, we compared the outcomes between ETV and TDF in HBV-related advanced HCC patients who underwent FOLFOX-HAIC.

Methods:

A total of 683 patients diagnosed with HBV-related HCC who underwent FOLFOX-HAIC and received TDF or ETV between January 2016 and December 2021 were included. Overall survival (OS), progression-free survival (PFS), HBV reactivation, and liver function of patients were compared between the ETV and TDF groups by propensity score matching (PSM).

Results:

In the PSM cohort, for all patients and patients with ≥ 4 cycles of FOLFOX-HAIC, the median OS in the ETV group (15.2 months, 95% CI 13.0-17.4 months; 16.6 months, 95% CI 14.8-18.5 months; respectively) was shorter than that in the TDF group (23.0 months, 95% CI 10.3-35.6 months; 27.3 months, 95% CI 16.5-NA months; p=0.024, p=0.028; respectively). The median PFS in the ETV group (8.7 months, 95% CI 7.9-9.5 months; 8.9 months, 95% CI 8.0-9.8 months; respectively) was also shorter than that in the TDF group (11.8 months, 95% CI 8.0-15.6 months; 12.7 months, 95% CI 10.8-14.6 months; p=0.036, p=0.025; respectively). The rate of HBV reactivation in the ETV group was higher than that in the TDF group (12.3% vs 6.3%, p=0.040; 16.5% vs 6.2%, p=0.037, respectively). For liver function, the rate of ALBI grade that remained stable or improved in the ETV group was lower than that in the TDF group (44.6% vs 57.6%, p=0.006; 37.2% vs 53.8%, p=0.019, respectively).

Conclusion:

Compared with ETV, TDF was associated with a better prognosis, lower proportion of HBV reactivation, and better preservation of liver function in advanced HBV-HCC patients who underwent FOLFOX-HAIC, especially those who received ≥ 4 cycles.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Hepatocell Carcinoma Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Hepatocell Carcinoma Ano de publicação: 2023 Tipo de documento: Article
...